Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator

Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Jun Shimada, Takashi Futamura, Hiroshi Yamashita, Nobuaki Ito, Robert D. McQuade, Arne Mørk, Alan L. Pehrson, Morten Hentzer, Vibeke Nielsen, Christoffer Bundgaard, Jørn Arnt, Tine Bryan Stensbøl, Tetsuro Kikuchi

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors. In particular, it bound with high affinity (K i < 1 nM) to human serotonin 1A (h5-HT 1A )-, h5-HT 2A -, long form of human D 2 (hD 2L )-, hα 1B -, and hα 2C -adrenergic receptors. It displayed partial agonism at h5-HT 1A and hD 2 receptors in cloned receptor systems and potent antagonism of h5-HT 2A receptors and hα 1B/2C -adrenoceptors. Brexpiprazole also had affinity (K i < 5 nM) for hD 3- , h5-HT 2B -, h5-HT 7 -, hα 1A -, and hα 1D -adrenergic receptors, moderate affinity for hH 1 (K i = 19 nM), and low affinity for hM 1 receptors (K i > 1000 nM). Brexpiprazole potently bound to rat 5-HT 2A and D 2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT 1A receptor binding potency. Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT 2A antagonism. Furthermore, in vivo D 2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D 2 partial agonist activity. In particular, based on a lower intrinsic activity at D 2 receptors and higher binding affinities for 5-HT 1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D 2 receptor agonist-and antagonist-related adverse effects. In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacology, which may offer novel treatment options across a broad spectrum of central nervous system disorders.

Original languageEnglish
Pages (from-to)589-604
Number of pages16
JournalJournal of Pharmacology and Experimental Therapeutics
Volume350
Issue number3
DOIs
StatePublished - Sep 2014

Fingerprint

Dopamine
Serotonin
Adrenergic Receptors
Receptor, Serotonin, 5-HT1A
brexpiprazole
In Vitro Techniques
Receptor, Serotonin, 5-HT2A
Homovanillic Acid
Central Nervous System Diseases
Reserpine
Microdialysis
Dopamine Receptors
Nucleus Accumbens
Prefrontal Cortex
Acetic Acid
Antipsychotic Agents
Psychiatry
Norepinephrine
Head
Pharmacology

Cite this

Maeda, Kenji ; Sugino, Haruhiko ; Akazawa, Hitomi ; Amada, Naoki ; Shimada, Jun ; Futamura, Takashi ; Yamashita, Hiroshi ; Ito, Nobuaki ; McQuade, Robert D. ; Mørk, Arne ; Pehrson, Alan L. ; Hentzer, Morten ; Nielsen, Vibeke ; Bundgaard, Christoffer ; Arnt, Jørn ; Stensbøl, Tine Bryan ; Kikuchi, Tetsuro. / Brexpiprazole I : In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. In: Journal of Pharmacology and Experimental Therapeutics. 2014 ; Vol. 350, No. 3. pp. 589-604.
@article{35d4a6c629a84a7d8d2b0037caf7e70b,
title = "Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator",
abstract = "Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors. In particular, it bound with high affinity (K i < 1 nM) to human serotonin 1A (h5-HT 1A )-, h5-HT 2A -, long form of human D 2 (hD 2L )-, hα 1B -, and hα 2C -adrenergic receptors. It displayed partial agonism at h5-HT 1A and hD 2 receptors in cloned receptor systems and potent antagonism of h5-HT 2A receptors and hα 1B/2C -adrenoceptors. Brexpiprazole also had affinity (K i < 5 nM) for hD 3- , h5-HT 2B -, h5-HT 7 -, hα 1A -, and hα 1D -adrenergic receptors, moderate affinity for hH 1 (K i = 19 nM), and low affinity for hM 1 receptors (K i > 1000 nM). Brexpiprazole potently bound to rat 5-HT 2A and D 2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT 1A receptor binding potency. Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT 2A antagonism. Furthermore, in vivo D 2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D 2 partial agonist activity. In particular, based on a lower intrinsic activity at D 2 receptors and higher binding affinities for 5-HT 1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D 2 receptor agonist-and antagonist-related adverse effects. In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacology, which may offer novel treatment options across a broad spectrum of central nervous system disorders.",
author = "Kenji Maeda and Haruhiko Sugino and Hitomi Akazawa and Naoki Amada and Jun Shimada and Takashi Futamura and Hiroshi Yamashita and Nobuaki Ito and McQuade, {Robert D.} and Arne M{\o}rk and Pehrson, {Alan L.} and Morten Hentzer and Vibeke Nielsen and Christoffer Bundgaard and J{\o}rn Arnt and Stensb{\o}l, {Tine Bryan} and Tetsuro Kikuchi",
year = "2014",
month = "9",
doi = "10.1124/jpet.114.213793",
language = "English",
volume = "350",
pages = "589--604",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

Maeda, K, Sugino, H, Akazawa, H, Amada, N, Shimada, J, Futamura, T, Yamashita, H, Ito, N, McQuade, RD, Mørk, A, Pehrson, AL, Hentzer, M, Nielsen, V, Bundgaard, C, Arnt, J, Stensbøl, TB & Kikuchi, T 2014, 'Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator', Journal of Pharmacology and Experimental Therapeutics, vol. 350, no. 3, pp. 589-604. https://doi.org/10.1124/jpet.114.213793

Brexpiprazole I : In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. / Maeda, Kenji; Sugino, Haruhiko; Akazawa, Hitomi; Amada, Naoki; Shimada, Jun; Futamura, Takashi; Yamashita, Hiroshi; Ito, Nobuaki; McQuade, Robert D.; Mørk, Arne; Pehrson, Alan L.; Hentzer, Morten; Nielsen, Vibeke; Bundgaard, Christoffer; Arnt, Jørn; Stensbøl, Tine Bryan; Kikuchi, Tetsuro.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 350, No. 3, 09.2014, p. 589-604.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brexpiprazole I

T2 - In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator

AU - Maeda, Kenji

AU - Sugino, Haruhiko

AU - Akazawa, Hitomi

AU - Amada, Naoki

AU - Shimada, Jun

AU - Futamura, Takashi

AU - Yamashita, Hiroshi

AU - Ito, Nobuaki

AU - McQuade, Robert D.

AU - Mørk, Arne

AU - Pehrson, Alan L.

AU - Hentzer, Morten

AU - Nielsen, Vibeke

AU - Bundgaard, Christoffer

AU - Arnt, Jørn

AU - Stensbøl, Tine Bryan

AU - Kikuchi, Tetsuro

PY - 2014/9

Y1 - 2014/9

N2 - Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors. In particular, it bound with high affinity (K i < 1 nM) to human serotonin 1A (h5-HT 1A )-, h5-HT 2A -, long form of human D 2 (hD 2L )-, hα 1B -, and hα 2C -adrenergic receptors. It displayed partial agonism at h5-HT 1A and hD 2 receptors in cloned receptor systems and potent antagonism of h5-HT 2A receptors and hα 1B/2C -adrenoceptors. Brexpiprazole also had affinity (K i < 5 nM) for hD 3- , h5-HT 2B -, h5-HT 7 -, hα 1A -, and hα 1D -adrenergic receptors, moderate affinity for hH 1 (K i = 19 nM), and low affinity for hM 1 receptors (K i > 1000 nM). Brexpiprazole potently bound to rat 5-HT 2A and D 2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT 1A receptor binding potency. Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT 2A antagonism. Furthermore, in vivo D 2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D 2 partial agonist activity. In particular, based on a lower intrinsic activity at D 2 receptors and higher binding affinities for 5-HT 1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D 2 receptor agonist-and antagonist-related adverse effects. In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacology, which may offer novel treatment options across a broad spectrum of central nervous system disorders.

AB - Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors. In particular, it bound with high affinity (K i < 1 nM) to human serotonin 1A (h5-HT 1A )-, h5-HT 2A -, long form of human D 2 (hD 2L )-, hα 1B -, and hα 2C -adrenergic receptors. It displayed partial agonism at h5-HT 1A and hD 2 receptors in cloned receptor systems and potent antagonism of h5-HT 2A receptors and hα 1B/2C -adrenoceptors. Brexpiprazole also had affinity (K i < 5 nM) for hD 3- , h5-HT 2B -, h5-HT 7 -, hα 1A -, and hα 1D -adrenergic receptors, moderate affinity for hH 1 (K i = 19 nM), and low affinity for hM 1 receptors (K i > 1000 nM). Brexpiprazole potently bound to rat 5-HT 2A and D 2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT 1A receptor binding potency. Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT 2A antagonism. Furthermore, in vivo D 2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D 2 partial agonist activity. In particular, based on a lower intrinsic activity at D 2 receptors and higher binding affinities for 5-HT 1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D 2 receptor agonist-and antagonist-related adverse effects. In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacology, which may offer novel treatment options across a broad spectrum of central nervous system disorders.

UR - http://www.scopus.com/inward/record.url?scp=84903982078&partnerID=8YFLogxK

U2 - 10.1124/jpet.114.213793

DO - 10.1124/jpet.114.213793

M3 - Article

C2 - 24947465

AN - SCOPUS:84903982078

VL - 350

SP - 589

EP - 604

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -